Pocket Program - CROI

Poster Listings
Session 100 CROI 2013
520 Genome-wide Association Study of Atazanavir
Daniel Johnson* 1 , C Venuto2 , E Daar3 , G Morse4 , P Sax5 , M Fischl6 ,
A Collier7 , P McLaren8,9 , M Ritchie10 , D Haas1 , and ACTG
1 2 Vanderbilt Univ Sch of Med, Nashville, TN, US;; Univ of Rochester, NY,
US;; 3Los Angeles Biomed Res Inst at Harbor-UCLA Med Ctr, Torrance,
CA, US;; 4Univ at Buffalo, SUNY, US;; 5 Boston, MA, US;; 6Univ of Miami Miller Sch of Med, FL, US;; 7Univ of
Washington, Seattle, US;; 8Broad Inst of MIT and Harvard, Cambridge,
MA, US;; 9Ecole Polytech Federale de Lausanne, Univ of Lausanne,
Switzerland;; and 10 529 Tenofovir Alafenamide Pharmacokinetics in Renal Impairment:
Srini Ramanathan*
Pennsylvania State Univ, Univ Park, US
1 , J Custodio1 , M Fordyce1 , W Garner1 , M Vimal1 ,
G Klein2 , K Farbakhsh3 , P Pergola4 , A Cheng1 , and B Kearney1 1 2 3 Gilead Sci, Inc, CA, US;; APEX GmbH, Munich, Germany;; DaVita Clin Res,
Minneapolis, Minnesota, US;; and 4Renal Assoc, PA, San Antonio, Texas, US
c Wednesday, 2:30-4 pm; Hall B2
Session 103–Poster Abstracts
Compartment Penetration of ARV
c Monday, 2:30-4 pm; Hall B2
Session 101–Poster Abstracts
ARV Drug Exposure, Safety, and Efficacy
521 Efavirenz Pharmacokinetics Are Independently Associated
Adriana Andrade* 1 , G Baheti2 , L Smeaton3 , M Yang3 , N Kumarasamy4 ,
T Flanigan5 , J Hakim6 , K Klingman7 , T Campbell8 , C Fletcher2 , and ACTG
5175 Team
1 2 Johns Hopkins Univ, Baltimore, MD, US;; Univ of Nebraska Med Ctr,
Omaha, US;; 3Statistical and Data Analysis Ctr, Harvard Sch of Publ Hlth,
Boston, MA, US;; 4YR Gaitonde Ctr for AIDS Res and Ed, Chennai, India;;
5 6 7 Miriam Hosp, Providence, RI, US;; Univ of Zimbabwe, Harare;; NIAID,
NIH, Bethesda, MD, US;; and 8Univ of Colorado Denver, Aurora, US
522
Ritonavir Use—Increase Tenofovir Exposure in a Large
Unselected Cohort of HIV + Women
S Baxi1 , R Greenblatt1 , P Bacchetti1 , K Anastos2 , C Ponath1 , M Cohen3 ,
H Minkoff4 , S Gange5 , Monica Gandhi* 1 , and Womens Interagency
HIV Study
1 2 Univ of California, San Francisco, US;; Albert Einstein Coll of Med,
Bronx, NY, US;; 3Stroger Cook County Hosp, Chicago, IL, US;; 4SUNY Downstate Med Ctr, Brooklyn, US;; and 5 530
and Blood Plasma: Applying the Law of Mass Action to
Predict Protein-free Drug Concentration
Lindsay Avery*, N Sacktor, J McArthur, and C Hendrix
Johns Hopkins Univ Sch of Med, Baltimore, MD, US
531 Single and Multiple Dose Dolutegravir Pharmacokinetics in
the Genital Tract and Colorectum of HIV
Johns Hopkins Univ Bloomberg
Sch of Publ Hlth, Baltimore, MD, US
Men and Women
Benjamin Greener* 1 , J Adams1 , K Patterson2 , H Prince2 , C Sykes1 ,
M Wai1 , J Dumond1 , N Shaheen2 , M Cohen2 , and A Kashuba1,2 1Univ of North Carolina at Chapel Hill Eshelman Sch of Pharmacy, US
and 2Univ of North Carolina at Chapel Hill Sch of Med, US
532
in HIV Prevention
Melanie Nicol* 1 , Y Fedoriw1 , M Mathews1 , J Micheli2 , D Kroetz2 ,
and A Kashuba1 1 2 Univ of North Carolina at Chapel Hill, US and Univ of California,
San Francisco, US
c Wednesday, 2:30-4 pm; Hall B2
Session 104–Poster Abstracts
ARV Drug Interactions
523
and Drug Exposure in HIV + 533 In vitro Induction of Influx and Efflux Transporters and
Patients
Cristina Gervasoni*, P Meraviglia, S Landonio, S Baldelli, S Fucile,
L Castagnoli, E Clementi, M Galli, A Riva, and D Cattaneo
Beth Williamson*
Luigi Sacco Hosp, Milan, Italy
524
Exposure-safety Relationship following Administration of
Srini Ramanathan*, Y-P Liu, H Wang, A Plummer, M Fordyce,
L Zhong, F Jin, A Cheng, J Szwarcberg, and B Kearney
Gilead Sci, Inc, Foster City, CA, US
1 , K Dooley2 , D Back1 , and A Owen1 1 2 Univ of Liverpool, UK and Johns Hopkins Univ, Baltimore, MD, US
534
L Zhu, C Hwang, V Shah, M Hruska, P Hu, B Vakkalagadda, M Furlong,
X Xu, G Hanna, and Richard Bertz*
Bristol-Myers Squibb, Princeton, NJ, US
c Tuesday, 2:30-4 pm; Hall B2
Session 102–Poster Abstracts
ARV Pharmacokinetics: New Assays, Drugs, and
Special Populations
40 20th Conference on Retroviruses and Opportunistic Infections
535 Dolutegravir Has No Effect on Pharmacokinetics of Methadone
or Oral Contraceptives with Norgestimate and Ethinyl Estradiol
I Song 1 , S Mark 1 , J Borland 1 , S Chen 1 , T Wajima 2 , A Peppercorn 1 ,
and Stephen Piscitelli* 1
1 GlaxoSmithKline, Research Triangle Park, NC, US and Mississauga,
Canada and 2 Shionogi and Co, Ltd, Osaka, Japan
525 Tenofovir Diphosphate in Dried Blood Spots in HIV vs HIV +
Individuals
Jose Castillo-Mancilla* 1 , J Rower1 , J-H Zheng1 , A Meditz1 , E Gardner2 ,
K McAllister1 , B Klein1 , J Kiser1 , L Bushman1 , and P Anderson1 1 2 Univ of Colorado-AMC, Aurora, US and Denver Hlth Med Ctr, CO, US
526
Chromatography and Self-reported Adherence in Patients on
ART
Eva Muro* 1,2 , L George1 , W Dolmans3 , D Burger3,4 , and E Kisanga1,2 1 2 Kilimanjaro Christian Med Univ Coll, Moshi, Tanzania;; Kilimanjaro
Clinical Res Inst, Moshi, Tanzania;; 3Inst for Infection, Inflammation and
Immunity, Nijmegen, The Netherlands;; and 4Radboud Univ Med Ctr,
Nijmegen, The Netherlands
527
Matt Anderson* 1 , J Gilmartin1 , M Robberechts1 , I De Lepeleire1 ,
L van Bortel2 , M Dockendorf Fallon1 , Y Guo1 , J Wagner1 , and J Butterton1 1 2 Merck Sharp & Dohme, Corp, Whitehouse Station, NJ, US and Drug
Res Unit, Ghent, Belgium
528 Pharmacokinetic Study of Raltegravir in HIV + Patients with
C Barau1 , J Braun2 , C Vincent2 , S Haim-Boukobza3,4 , J-M Molina5,6 ,
P Miailhes7,8 , J-P Aboulker2 , J-C Duclos-Vallee3,9 , A-M Taburet1 ,
Elina Teicher* 1,3 , and ANRS 148 Study Group
1 2 Bicetre Hosp, Le Kremlin-Bicetre, France;; INSERM SC10-US019,
Villejuif, France;; 3Paul-Brousse Hosp, Villejuif, France;; 4INSERM U785,
Villejuif, France;; 5St Louis Hosp, Paris, France;; 6 536
sparing Regimen Raltegravir plus Nevirapine in HIV-1
Paris VII Univ, France;;
7 8 Croix-Rousse Hosp, Lyon, France;; INSERM U1052, Lyon, France;; and
9CHB UMR-S 785, Villejuif, France
+ Patients
Chiara Montrucchio* 1 , A Calcagno1 , M Lanzafame2 , G Cenderello3 ,
M Simiele1 , MC Tettoni1 , P Bigliano1 , A D’Avolio1 , G Di Perri1 ,
and S Bonora1 1 2 3 Univ of Torino, Italy;; GB Rossi Univ Hosp, Verona, Italy;; and San
Martino Hosp Genoa, Univ of Genoa, Italy
537
and HIV-1 NNRTI Rilpivirine
Elizabeth Rhee*, H-P Feng, F Xuan, W Lin, C Smith, Y Zhu,
and J Butterton
Merck & Co, Inc, Whitehouse Station, NJ, US
538
Co-administration in Hepatitis C Virus Infected Patients
Adriana Andrade* 1 , C Hendrix1 , E Fuchs1 , C Radebaugh1 ,
M Sulkowski1 , L Bushman2 , M Ray2 , and J Kiser2 1 2 Johns Hopkins Univ, Baltimore, MD, US and Univ of Colorado Denver,
Aurora, US
539 Pharmacokinetics of Two Doses of Raltegravir in
H Sauvageon1 , B Grinsztejn2 , V Arnold3 , V Veloso2 , C Vorsatz2 , JH Pilotto4 ,
C Grondin3 , G Chene3 , Anne-Marie Taburet* 5 , and J-M Molina1,6 1 2 Hosp St Louis, Paris, France;; IPEC, Fiocruz, Rio de Janeiro, Brazil;;
3 4 INSERM U897, Univ Bordeaux, France;; Hosp Geral de Nova Iguacu,
Brazil;; 5Hosp Bicetre, Kremlin-Bicetre, France;; and 6Univ Paris Diderot,
Paris, France